Escherichia coli Nissle 1917
Selected indexed studies
- Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. (Trends Pharmacol Sci, 2022) [PMID:35232591]
- Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications. (Biotechnol Adv, 2023) [PMID:37343690]
- Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment. (Gut Microbes, 2022) [PMID:35491895]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. (2022) pubmed
- Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. (2022) pubmed
- Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications. (2023) pubmed
- Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment. (2022) pubmed
- Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. (2020) pubmed
- Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications. (2022) pubmed
- E. coli Nissle 1917 ameliorates mitochondrial injury of granulosa cells in polycystic ovary syndrome through promoting gut immune factor IL-22 via gut microbiota and microbial metabolism. (2023) pubmed
- Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain. (2024) pubmed
- Colibactin-driven colon cancer requires adhesin-mediated epithelial binding. (2024) pubmed
- Expectations for employing Escherichia coli Nissle 1917 in food science and nutrition. (2025) pubmed